March Biosciences Secures $4.8M Investment from Cancer Focus Fund

USA, Houston-based clinical stage biotech firm, March Biosciences, has successfully raised $4.8 million from the Cancer Focus Fund, LP, an investment fund established in collaboration with The University of Texas MD Anderson Cancer Center. Led by CEO Sarah Hein, March Biosciences focuses on addressing challenging cancers that are unresponsive to existing immunotherapies. The funding will be used to accelerate the Phase 2 clinical trial of MB-105, the company's chimeric antigen receptor-T cell (CAR-T) therapy designed to target CD5-positive relapsed/refractory T-cell lymphoma. The specially engineered therapy aims to preserve healthy T-cells while effectively targeting malignant T-cells expressing CD5.